The first true oral GLP-1 competitor, orforglipron (Eli Lilly, brand name Foundayo), is a non-peptide agonist expected to launch at a significantly lower price point
clinicaltrials.gov NCT03914326 [88]) is underway to investigate the effect of oral semaglutide treatment on CV outcomes
Appropriate treatment options depend on how your body is currently functioning, not just your goals
The vibrant lifestyle of Austin and its neighboring communitiesCedar Park, Leander, Round Rock, Georgetown, Pflugerville, Lakeway and Northwest Austinoffers endless opportunities for outdoor adventures, entrepreneurial pursuits and busy family life
Combination therapy for non-alcoholic steatohepatitis: Rationale, opportunities and challenges